Skip to main content
. Author manuscript; available in PMC: 2016 Aug 31.
Published in final edited form as: Cancer Control. 2011 Jul;18(3):196–203. doi: 10.1177/107327481101800307

Fig 1.

Fig 1

Schematic representing IGF1R/HER2 intersecting pathways. Either IGF signaling or HER2 dimerizing with HER3 on ligand (lig) binding will lead to activation of phosphoinositol 3 kinase (PI3K), which then activates Akt and its downstream effectors. Either IGF signaling or HER2 dimerizing with HER1 (also EGFR) on ligand binding will activate GRB2 and SOS, which then activate RAS/RAF signaling.